Back to Studies

IMPAACT 2026

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Study Status

Pending

Locality

US & Non-US

DAIDS Number

38609

IND Number

146262

Clinical Trials Link

Summary

IMPAACT 2026 is a Phase IV, prospective, pharmacokinetic (PK) study of selected antiretroviral (ARV) and anti-tuberculosis (TB) drugs during pregnancy and postpartum. The study is designed to evaluate the following: the PK of ARV medicines used in clinical care during pregnancy and postpartum; the PK of ARVs when used in combination with first-line TB medicines in clinical care during pregnancy and postpartum; the PK of second-line TB medicines when used in clinical care during pregnancy and postpartum; the kinetics of placental and breastmilk transfer of long-acting injectable ARVs after maternal dosing during pregnancy; and the kinetics of breastmilk transfer of other select ARVs from mother to child during breastfeeding.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...